Why the study?
Does losartan improve treatment persistence compared to non-losartan ARBs in uncomplicated, treatment-naïve hypertensive patients?
Does losartan improve treatment persistence compared to non-losartan ARBs in uncomplicated, treatment-naïve hypertensive patients?
Initial choice of losartan versus non-losartan ARBs does not significantly affect 12-month treatment persistence in uncomplicated, treatment-naïve hypertensive patients.
No difference in persistence between losartan and other ARBs; leaves open class effects on long-term adherence.
We identified 55 504 uncomplicated, treatment-naïve hypertensive patients who started angiotensin II receptor blockers (ARBs) in 2012 from national claims data. The proportion of patients remaining on any hypertension treatment at 12 months and the adherence rate were similar between the losartan cohort (66.82% and 68.25%) and the nonlosartan ARB cohort (67.48% and 69.01%). After adjusting for confounding factors, there was no difference in persistence (aHR 0.98, 95% confidence interval (CI) 0.95-1.01) on hypertension treatment between losartan and nonlosartan ARB cohort. Post hoc analysis showed that patients initially prescribed eprosartan, irbesartan (both, aHR 1.33), and telmisartan (aHR 1.11) were more likely to discontinue the initial drug, whereas valsartan initiators (aHR 0.96) were less likely compared with losartan initiators.
No takes yet. Share an insight, caveat, or question.
Ah et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: